TARSUS PHARMACEUTICALS, INC. Operating Lease, Weighted Average Discount Rate, Percent
TARSUS PHARMACEUTICALS, INC. (TARS) had Operating Lease, Weighted Average Discount Rate, Percent of 11.40% as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Leases
us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent · last filed 2026-08-06
- 2026-06-30: Operating Lease, Weighted Average Discount Rate, Percent 11.40%.
- 2026-03-31: Operating Lease, Weighted Average Discount Rate, Percent 11.40%.
- 2025-12-31: Operating Lease, Weighted Average Discount Rate, Percent 11.40%.
- 2025-09-30: Operating Lease, Weighted Average Discount Rate, Percent 11.40%.
| Period end | Operating Lease, Weighted Average Discount Rate, Percent | Operating Lease, Weighted Average Discount Rate, Percent as first filed |
|---|---|---|
| 2026-06-30 | 11.40% 10-Q · filed 2026-08-06 | |
| 2026-03-31 | 11.40% 10-Q · filed 2026-05-06 | |
| 2025-12-31 | 11.40% 10-Q · filed 2026-08-06 | |
| 2025-09-30 | 11.40% 10-Q · filed 2025-11-04 | |
| 2025-06-30 | 11.00% 10-Q · filed 2025-08-06 | |
| 2025-03-31 | 11.00% 10-Q · filed 2025-05-01 | |
| 2024-12-31 | 11.00% 10-K · filed 2026-02-23 | |
| 2024-09-30 | 10.00% 10-Q · filed 2024-11-13 | |
| 2024-06-30 | 11.00% 10-Q · filed 2025-08-06 | 10.00% 10-Q · filed 2024-08-08 |
| 2024-03-31 | 10.00% 10-Q · filed 2025-05-01 | |
| 2023-12-31 | 10.00% 10-K · filed 2026-02-23 | |
| 2023-09-30 | 10.00% 10-Q · filed 2023-11-09 | |
| 2023-06-30 | 10.00% 10-Q · filed 2023-08-10 | |
| 2022-12-31 | 10.00% 10-K · filed 2025-02-25 | |
| 2022-09-30 | 10.00% 10-Q · filed 2022-11-09 | |
| 2022-06-30 | 10.00% 10-Q · filed 2022-08-11 | |
| 2022-03-31 | 10.00% 10-Q · filed 2022-05-11 | |
| 2021-12-31 | 10.00% 10-K · filed 2022-03-14 | |
| 2021-09-30 | 10.00% 10-Q · filed 2021-11-10 | |
| 2021-06-30 | 10.00% 10-Q · filed 2021-08-05 | |
| 2021-03-31 | 10.00% 10-Q · filed 2021-05-11 | |
| 2020-12-31 | 10.00% 10-K · filed 2021-03-31 | |
| 2020-09-30 | 10.00% 10-Q · filed 2020-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |